Background: The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients. Methods: A total of 238 HIV-HCV-coinfected patients (74% male, mean ±sd age 40 ±5 years, mean alcohol intake <50 g/day and 38% HCV genotype 2 or 3), treated by standard or pegylated interferon-α2b plus ribavirin during 48 weeks were studied. Liver biopsies were assessed before treatment. Patients were considered to have IR when the homeostasis model assessment of IR (HOMA-IR) was >2.5. Multiple logistic regression with stepwise selection was used to estimate independent factors associated with sustained virological response (SVR).
Results: IR was present in 32% and significant liver fibrosis (Metavir≥F2) in 74% of patients. Patients with SVR (96/238 [40%]) were more likely to be infected with HCV genotype 2 or 3 (54% versus 27%; P<0.0001), and had more severe liver fibrosis (≥F3; 45% versus 30%; P=0.03). By multivariate analysis, a HOMA-IR>2.5 had a negative effect on the SVR (odds ratio 0.49 [95% confidence interval 0.26-0.92]; P=0.05). Conclusions: A high HOMA-IR level is frequently found in HIV-HCV-coinfected patients and is associated with a reduced SVR rate. Improving insulin sensitivity might be a useful adjunct to HCV therapy in HIV-HCV-coinfected patients.
In hepatitis C virus (HCV)-infected patients, host and viral factors influence the sustained virological response (SVR) rate to combined interferon/ribavirin therapy. HCV infection is now recognized as a systemic disease involving lipid metabolism, oxidative stress and mitochondrial function [1] [2] [3] . Recent studies support the observation that HCV-infected patients who have significant insulin resistance (IR) and hepatic steatosis are less likely to achieve SVR to interferon-based therapy [4, 5] . IR can be measured by using the glucose clamp technique, which is regarded as the reference method for an accurate assessment of in vivo insulin sensitivity [6] . However, this method is labourious, expensive, and therefore unsuitable for large-scale or epidemiological studies. Several alternative methods to evaluate insulin sensitivity have been proposed during the past two decades [7] [8] [9] [10] [11] [12] . Although generally less complex and less troublesome than the glucose clamp technique, none of them is as simple as is necessary in large-scale studies involving hundreds or thousands of participants. The homeostasis model assessment (HOMA) of insulin sensitivity was proposed as a simple and inexpensive alternative to more sophisticated techniques [13] . This method derives an estimate of insulin sensitivity from the [4] . Owing to common routes of transmission, that is, intravenous drug use and transfusion, one-third of patients infected with HIV in the United States and Europe are coinfected with the HCV [6, 7] . HCV appears to have a more progressive course in coinfected patients than in those with HCV monoinfection [8] [9] [10] [11] [12] [13] . Mortality associated with opportunistic infections has dramatically decreased with the widespread use of highly active antiretroviral therapy. However, the liver-disease-related death rate is increasing. HCV-associated chronic liver disease accounts for 12% to >45% of overall mortality in HIV-infected patients [14] [15] [16] [17] [18] [19] [20] [21] . HIV-HCV-coinfected patients might achieve an SVR with the combined treatment of pegylated interferon plus ribavirin [22] [23] [24] [25] , although less frequently than in HCV-monoinfected patients.
The aim of this study was to assess the effect of IR on the response to HCV therapy in HIV-HCV-coinfected patients.
Methods

Patients
This study retrospectively analysed serum samples from 238 HIV-HCV-coinfected patients, naive for HCV treatment, who underwent percutaneous liver biopsy before their inclusion in the prospective multicentre RIBAVIC ANRS-HC02 trial. The HOMAVIC study is a substudy of the RIBAVIC trial, which aimed to assess the effect of IR on the response to HCV therapy. The main characteristics of RIBAVIC ANRS-HC02 study patients have been published previously [24] . In the trial, 412 HIV-HCV-coinfected patients were included. Frozen serum samples were collected for only 361 patients. In addition, 40 serum samples were excluded for technical reasons. From the remaining 321 serum samples, 83 samples were excluded because of missing baseline or no central evaluation of liver biopsy, no assessment of fasting insulinaemia nor fasting glycaemia (for HOMA-IR calculation), or untreated patients. Finally, 238 samples from patients with baseline serum sample assessment and liver biopsy evaluation by an independent pathologist were included. No significant difference between included and excluded patients was observed (data not shown).
Histological assessment
Liver biopsies were fixed in formalin and embedded in paraffin. All biopsies were stained with at least the two basic stains (haematoxylin-eosin) and Masson's trichrome. Upon request, other staining, such as with Sirius red or reticulin, was performed. Liver biopsies were analysed by the local pathologist of each centre at the time of inclusion in the RIBAVIC ANRS-HC02 trial for fibrosis stage and activity grade according to the Metavir scoring system [26] . Liver biopsies were re-evaluated for patients included in this study by an independent pathologist (PB) without knowledge of the HOMA-IR values. Fibrosis was staged on a scale of 0-4: F0, no fibrosis; F1, portal fibrosis without septa; F2, few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. Activity grading by the Metavir system (based on the intensity of periportal and lobular necroinflammation) was scored as follows: A0, no histological activity; A1, mild activity; A2, moderate activity; and A3, severe activity. Liver steatosis was graded as none (0%), minimal (<10% hepatocytes), mild to moderate (10-30%) or severe (>30%). The cutoff value for clinically significant steatosis was ≥10%.
Anthropometric and laboratory evaluations
The body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). Patients with a BMI>25 kg/m 2 were considered overweight. After an overnight fast of 12 h, venous blood samples were drawn to determine serum levels of insulin and glucose. γ-Glutamyl-transpeptidase (GGT), alanine aminotrasferase (ALT) and fasting glucose were analysed using a Beckman Coulter Synchron CX7 analyser (Beckman Coulter France SA, Roissy, France). Insulin was analysed using an Abbott Axsym Analyzer (Abbott France, Rungis, France). HOMA-IR was calculated using the following equation: HOMA-IR= insulin (mU/ ml)•(glycaemia [mmol/l]/22.5). IR was graded using the HOMA-IR score [27] . Patients with HOMA-IR values >2.5 were considered to have IR [28, 29] . α-Fetoprotein was tested by using commercially available immunometric assays (Architect AFP assay; Abbott France).
Statistical analyses
Fisher's exact or χ 2 tests were used to compare proportions. The Cochran-Mantel-Haenszel test was used to compare multiple proportions. Mann-Whitney or Kruskall-Wallis tests were used to compare means. Significance was accepted at P<0.05 based on two-sided tests. Multiple logistic regression with forward stepwise variable selection was used to identify independent factors associated with SVR and IR. P<0.05 and P>0.10 were used as the entry and exit criteria in the stepwise selection of predictors, respectively. All variables with a P-value ≤0.15 in univariate analyses were included in the multiple logistic regression model. Variables were described as odds ratios (ORs) with 95% confidence intervals (CIs). Figure 1 shows the probability of SVR by genotypes (1 or 4 versus 2 or 3) for patients after HCV treatment, according to the HOMA-IR level. The probability was assessed by the moving average method [30] . The lower rate of SVR with the HOMA-IR increase was found in genotype 2 or 3 patients. Genotype 2 or 3 patients had a higher SVR probability (P<0.0001). In Table 2 
Results
Discussion
HCV infection has recently become a major health problem in HIV-infected patients [14] [15] [16] [17] [18] [19] [20] [21] . HIV-HCVcoinfected patients achieve an SVR with combined treatment of pegylated interferon plus ribavirin less frequently than their HCV-monoinfected counterparts [22] [23] [24] [25] . Some factors are predictive of an SVR, such as genotype 2 or 3 infection [24] , low HCV viral load [31] and age <40 years.
The present study shows the negative effect of IR on SVR rates in HIV-HCV-coinfected patients. Our study highlighted the fact that IR is associated with a poor SVR rate, and conversely the SVR rate is associated with a lower HOMA-IR index. A great difference in the virological response to HCV therapy was observed according to the baseline degree of IR as measured by the HOMA-IR. The majority of patients (68%) with a baseline HOMA-IR<2.5 achieved an SVR. Patients with an SVR were more likely to have no IR (75%). A recent study by Romero-Gomez et al. [4] showed that IR, BMI and liver fibrosis were all associated with a decrease in SVR in HCV-monoinfected patients with an arbitrary cutoff value of HOMA>2. The rate of SVR in patients infected by HCV genotype 1 was 54% in patients without IR versus only 18% in patients with an altered HOMA-IR. Recent studies support the observation that HCV-infected patients who have significant IR and hepatic steatosis are less likely to achieve SVR with interferon-based therapy [4, 32, 33] . In HCVmonoinfected patients, significant steatosis remained a significant predictor of poorer response to HCV therapy, even after adjusting for HCV RNA, genotype, liver fibrosis and age. The reduced response to therapy was even more dramatic in patients with genotype 2 or 3 infection [34] . We found that advanced fibrosis is associated with a better virological response, a result that goes against the literature in HCV-monoinfected patients. However, in the literature on HIV-HCVcoinfected patients, the presence of severe liver fibrosis or cirrhosis was not reported as an independent negative predictor of the response to HCV treatment in the main trials [23, 24, 35, 36] .
In HIV-HCV-coinfected patients, conflicting data have been reported on the role of IR in predicting the response to antiviral therapy. Nasta et al. [37] reported that IR was an independent predictor of rapid virological response. These results were confirmed, in an analysis of 134 patients on interferon plus ribavirin treatment with a cutoff of the HOMA≥3.8 and its effect on SVR [35] . These authors even recommended the inclusion of HOMA-IR in the routine baseline evaluation of HIV-HCV-coinfected patients who are candidates for treatment with pegylated interferon plus ribavirin. By contrast, negative results have been recently reported in 155 HIV-HCV-coinfected patients who underwent a therapy with pegylated interferon plus ribavirin, using a HOMA-IR cutoff ≥4; nevertheless, they found a high prevalence of patients with HOMA≥4 (29%) [36] . In the literature, the HOMA has been analysed with different double strategies, that is, as a continuous variable as performed in our study, and as a dichotomous variable, categorized according to the median and to a cutoff value of 2 and 4. The value for IR estimated with the HOMA would not be easily defined and constitutes one of the limits of our study. The specific cutoff of 2.5 chosen for the determination of IR is arbitrary, as are the other cutoffs reported in other studies in the same field [4, [38] [39] [40] . Using a continuous HOMA-IR variable, we demonstrated that the probability of SVR tends to decrease as HOMA-IR increases in genotype 2 and 3 patients (Figure 1 ). This observation is linked to the role of IR as a specific feature of chronic hepatitis C in genotypes 1 and 4 [41] . Poustchi et al. [42] reported that in treatment-responsive genotype 2 and 3 patients, high HOMA-IR (>2) is associated with a reduced response. They suggest that improving insulin sensitivity might be a useful adjunct to antiviral therapy.
Our findings suggest that among factors that determine virological response to pegylated interferon plus ribavirin combination, IR and liver fibrosis are more significant than obesity and liver steatosis [43] . A reasonable hypothesis might be that there are significant interactions and 'cross-talk' between intracellular insulin and interferon signalling pathways. In experiments carried out on Huh-7 cells transfected by full-length HCV RNA, interferon-α blocks HCV replication. Intracellular factors deregulated by HCV and responsible for the state of IR often play promiscuous roles, as they are also involved in regulating the interferon-α signalling transduction. These include some members of the suppressor of cytokine signalling family [10] [11] [12] and the protein phosphatase 2A [13] . Modulating the levels and/or the activity of these factors might not only reverse hepatic IR but also help in establishing the interferon-α-induced antiviral state at the very site of HCV replication [44, 45] .
Another point to be discussed is the relationship between antiretroviral therapy and HOMA-IR. In the present study, the inclusion of protease inhibitor treatment in our logistic regression model did not significantly influence the HOMA-IR. We considered that pretreatment modulation of IR should not be based on the relationship between protease inhibitor and IR in HIV-HCV-coinfected patients.
The question of IR in both HCV-monoinfected and HIV-HCV-coinfected patients is far from settled, but the promotion of diet and lifestyle changes remains mandatory, considering that weight loss can improve liver fibrosis in HCV-monoinfected individuals. What has been learned about HCV and IR interaction in HCV-monoinfected patients could probably be applied in the setting of HIV-HCV-coinfected individuals, given that antiretroviral therapy represents a further risk factor for IR development, though further data are needed [46] . IR is a modifiable factor suggesting that response to HCV therapy might be improved by modulation of insulin signalling [25] [26] [27] .
Future prospective therapeutic trials are warranted to decrease IR in HIV-HCV-coinfected patients before or during pegylated interferon plus ribavirin treatment in order to increase SVR rates [47] [48] [49] [50] [51] [52] 
